Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.
Respir Res. 2021 Dec 22;22(1):317. doi: 10.1186/s12931-021-01914-6.
Respir Res. 2021.
PMID: 34937570
Free PMC article.